Investing

Nuvalent : NUVL

NUVL

Stock Data

$99.04

$1.24 (1.24%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Nuvalent Inc is a pioneering biopharmaceutical company focused on developing innovative cancer treatments. With a keen eye on addressing the limitations of current therapies, Nuvalent is advancing a portfolio of selective inhibitors designed to combat treatment resistance, minimize adverse events, and tackle brain metastases in cancer patients. Their leading candidates, including NVL-520 for lung cancer and NVL-655 for other cancers, are in clinical trials, showcasing the company's commitment to improving patient outcomes. Founded in 2017 and based in Cambridge, Massachusetts, Nuvalent is at the forefront of targeted cancer therapy research.

All Nuvalent Articles

1 Article

Chris MacDonald | Jan 20, 2026 at 10:42 AM EST

3 Biotech Stocks That Could Double In 2026

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors…